


# Sustainable pipeline expansion


- Oncology
- Rare Disease
- Neuroscience

Information shown  
as at end of June 2024



2L: second line; pNET: pancreatic neuroendocrine tumor; epNET: extrapancreatic neuroendocrine tumor;  
 mCRPC: metastatic castration-resistant prostate cancer; R<sup>2</sup>: lenalidomide + rituximab; FL: follicular lymphoma; PBC: primary biliary cholangitis;  
 FOP: fibrodysplasia ossificans progressiva; PSC: primary sclerosing cholangitis; Ax: aesthetics; Tx: therapeutics. <sup>1</sup> E.U. Disclaimer: trials are event-driven & timings can change.

# Construire un portefeuille de produits à long terme



**FOP:** fibrodysplasie ossifiante progressive; **CSP:** cholangite sclérosante primitive; **2L:** seconde ligne; **TNEep:** tumeurs neuroendocrines extra-pancréatiques ; **TNEp:** tumeurs neuroendocrines pancréatiques **CRPCm:** cancer de la prostate résistant à la castration métastatique; **R2:** lénalidomide + rituximab; **LF:** lymphome folliculaire; **AVB:** atrésie des voies biliaires; **SAG:** syndrome d'Alagille;<sup>1</sup> U.E.; **CBP:** cholangite biliaire primaire